Exelixis Full Year 2024 Earnings: EPS Beats Expectations
Exelixis Announces Final Five-Year Follow-up Results From CheckMate -9ER Trial Evaluating CABOMETYX (Cabozantinib) in Combination With Opdivo (Nivolumab) in Patients With Advanced Kidney Cancer at ASCO GU 2025
Exelixis to Participate in the Citi 2025 Virtual Oncology Leadership Summit
Barclays Maintains Equal-Weight on Exelixis, Raises Price Target to $29
H.C. Wainwright Maintains Exelixis(EXEL.US) With Buy Rating, Maintains Target Price $40
The Exelixis, Inc. (NASDAQ:EXEL) Annual Results Are Out And Analysts Have Published New Forecasts
Exelixis Hold Rating Maintained Amidst Stable Financials and Awaited Trial Data
Exelixis Earnings Call: Positive Growth and Ambitious Goals
A Glimpse Into The Expert Outlook On Exelixis Through 21 Analysts
Exelixis Is Maintained at Buy by Citigroup
EXEL Tops Q4 Earnings and Sales, Cabometyx Label Expansion in Focus
10 Health Care Stocks With Whale Alerts In Today's Session
Exelixis Is Maintained at Hold by Stifel
Exelixis Price Target Maintained With a $29.00/Share by Stephens & Co.
Piper Sandler Maintains Overweight on Exelixis, Raises Price Target to $38
Exelixis Analyst Ratings
BMO Capital Maintains Exelixis(EXEL.US) With Hold Rating, Maintains Target Price $40
Stifel Maintains Exelixis(EXEL.US) With Hold Rating, Announces Target Price $36
Truist Financial Maintains Exelixis(EXEL.US) With Buy Rating
A Quick Look at Today's Ratings for Exelixis(EXEL.US), With a Forecast Between $36 to $45